Qualigen Therapeutics Files 8-K
Ticker: AIXC · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1460702
| Field | Detail |
|---|---|
| Company | Qualigen Therapeutics, INC. (AIXC) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2025 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.001, $41,000,000, $2.246, $1,000, $6,800,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, 8-k
TL;DR
Qualigen Therapeutics filed an 8-K on 9/19/25 detailing material agreements and equity sales.
AI Summary
On September 19, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing indicates significant corporate activity, including definitive agreements and equity sales, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — 8-K filings often disclose material events that can lead to significant stock price volatility.
Key Numbers
- 001-37428 — Commission File Number (Identifies the company's filing with the SEC.)
- 26-3474527 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- September 19, 2025 (date) — Date of earliest event reported
- 2042 CORTE DEL NOGAL (address) — Business Address
- CARLSBAD (location) — City
- CALIFORNIA (location) — State
- 92011 (zip_code) — Business Address Zip Code
- RITTER PHARMACEUTICALS INC (company) — Former Company Name
- 20090402 (date) — Date of Name Change
FAQ
What type of material definitive agreement did Qualigen Therapeutics enter into?
The filing states that Qualigen Therapeutics, Inc. entered into a material definitive agreement on September 19, 2025, but the specific details of the agreement are not provided in this excerpt.
What is the significance of the 'Unregistered Sales of Equity Securities' item?
This indicates that the company may have sold equity securities without registering them with the SEC, which could have implications for dilution and regulatory compliance.
When was Qualigen Therapeutics, Inc. formerly known as Ritter Pharmaceuticals Inc?
The company's name was changed from Ritter Pharmaceuticals Inc. on April 2, 2009.
What is the primary business of Qualigen Therapeutics, Inc. according to its SIC code?
Qualigen Therapeutics, Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
What is the filing date and the earliest event date reported in this 8-K?
The filing date is September 25, 2025, and the earliest event reported is September 19, 2025.
Filing Stats: 2,570 words · 10 min read · ~9 pages · Grade level 14.7 · Accepted 2025-09-25 17:05:45
Key Financial Figures
- $0.001 — ch registered Common stock (par value $0.001 per share) QLGN The Nasdaq Stock Ma
- $41,000,000 — which the investors agreed to purchase $41,000,000 in cash (the "Offering") of the Company
- $2.246 — purchase price of the Common Stock was $2.246 per share and the purchase price for th
- $1,000 — rchase price for the Series B Stock was $1,000 per share (the "Stated Value"). At the
- $6,800,000 — p"). The Company intends to use up to $6,800,000 of the net cash proceeds from the Offer
- $2.47 — cise price per share of Common Stock of $2.47 (the "Placement Agent Warrants"). In ad
- $150,000 — reimburse the Placement Agent for up to $150,000 of its fees and expenses. The issuanc
Filing Documents
- form8-k.htm (8-K) — 63KB
- ex4-1.htm (EX-4.1) — 157KB
- ex4-2.htm (EX-4.2) — 126KB
- ex10-1.htm (EX-10.1) — 336KB
- ex10-2.htm (EX-10.2) — 204KB
- ex10-3.htm (EX-10.3) — 61KB
- ex10-4.htm (EX-10.4) — 55KB
- ex10-5.htm (EX-10.5) — 71KB
- ex10-6.htm (EX-10.6) — 100KB
- ex99-1.htm (EX-99.1) — 19KB
- 0001493152-25-014965.txt ( ) — 1585KB
- qlgn-20250919.xsd (EX-101.SCH) — 3KB
- qlgn-20250919_lab.xml (EX-101.LAB) — 33KB
- qlgn-20250919_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: September 25, 2025 By: /s/ Kevin A. Richardson II Hevin A. Richardson II Chief Executive Officer